On the basis of latest data in literature, PSMA PET/CT might be crucial for primary therapy assessment, because of its capability to detect even small but PSMA-avid pelvic lymph node metastasis outside the surgical template, thus leading to change in management in a considerable number of patients. The gene discussed is FOLH1; the disease is metastatic malignant neoplasm in the lymph nodes.